News Article | May 18, 2017
SAN RAFAEL, Calif.--(BUSINESS WIRE)--MedCision, LLC, the world leader in next-generation automated cell thawing for advanced therapies, today announced the company’s participation and Steering Committee membership in the inaugural meeting of the Phacilitate Special Interest Group on Automation taking place in Edinburgh, Scotland on May 30, 2017. The Phacilitate SIG is the only event to specifically examine automation relating to cell and gene therapy product characterization, quality testing, raw materials, and logistics, in addition to bioprocessing systems. By drawing together the cell and gene therapy sector’s top manufacturing decision makers with bioprocess developers and engineers, the SIG will provide a unique and exclusive think-tank to develop a roadmap for cost-effective, robust, and interconnected manufacturing and supply chain models. A list of participants can be found here. MedCision’s Chief Executive Officer Dr. Rolf Ehrhardt and Samuel Kent, Chief Commercial Officer, will facilitate sessions at the meeting and demonstrate the company’s latest technologies for vital preclinical and clinical drug handling. MedCision’s flagship product is the ThawSTAR® Automated Cell Thawing System, a first-of-its-kind, digitally enabled, automated instrument designed to de-risk thawing of live cell therapeutics. “There has never been a more exciting time to be working in cell therapy, and we are proud to be part of the founding team for this important industry event,” said Mr. Kent. “As the last step before a drug is administered by doctors, automation plays an important role in avoiding human error and ensuring predictable patient outcomes in a clinical environment. We believe the industry must work together to solve the hurdles in automating both the development and the provision of these critical live therapies, and we look forward to taking a leadership role.” David McCall, Content Director, Cell & Gene Therapy for Phacilitate commented: “Automated bioprocessing and supply chain-related technologies will be absolutely key to unlocking the potential of cell and gene therapies at commercial scale. We are delighted to be working with trailblazers and leaders in this field such as MedCision to help industry define a blueprint for the effective adoption and integration of these novel technologies.” Dr. Ehrhardt will also be speaking today on this topic at the World Advanced Therapies & Regenerative Medicine Congress in London. He will discuss how to solve the “last mile” problem in cell therapy, address standardization methods to reduce risk, and discuss automation in cell therapy workflows. MedCision develops automation technologies for vital clinical product handling processes. An industry first, the ThawSTAR Automated Cell Thawing System replaces uncontrolled and highly variable manual methods with a customizable algorithm to thaw each unique cell therapy product to maintain maximum cellular efficacy. MedCision’s global customers include pharmaceutical, medical, stem cell and other GMP facilities where consistent and repeatable outcomes are paramount. For more information please visit www.medcision.com or www.medcision.com/blog/.
News Article | April 28, 2017
We deeply analyzed Europe, the Middle East and Africa growth forecast indicators by the as well as the regional market conditions that including the product price, profit, utilization, supply, demand and industry growth rate — Europe, the Middle East and Africa Cell Counting Market– Forecast to 2021 The report firstly introduced Europe, the Middle East and Africa Cell Counting Market including classification, application and industry chain overview; Then we deeply analyzed Europe, the Middle East and Africa growth forecast indicators by the as well as the regional market conditions that including the product price, profit, utilization, supply, demand and industry growth rate etc. In the end, the report introduced medical suction device market SWOT analysis, PEST analysis, market share analysis and competitive landscape, company profiles by analyzing the major players. It is a depth research study on Europe, the Middle East and Africa Cell Counting Market. We are thankful for the support and assistance from Europe, the Middle East and Africa Cell Counting Market chain related technical experts and marketing experts during Research Team survey and interviews. 6 Europe, The Middle East And Africa Cell Counting Market, By End Users 6.1 Introduction 6.2 Hospitals And Research Institutions 6.3 Diagnostic Laboratories 6.4 Pharmaceutical & Biotechnology Companies, And Cros 6.5 Others 7 Europe, The Middle East And Africa Cell Counting Market, By Pharmacological Treatments 7.1 Introduction 7.2 Consumables 7.2.1 Reagents 7.2.2 Assay Kits 7.2.3 Microplates 7.2.4 Others 7.3 Instruments 7.3.1 Spectrophotometers 184.108.40.206 Single-Mode Readers 220.127.116.11 Multi-Mode Readers 7.3.2 Flow Cytometers 7.3.3 Cell Counters 18.104.22.168 Automated Cell Counters 22.214.171.124 Hemocytometers And Manual Cell Counters 7.3.4 Hematology Analyzers 7.4 Accessories 8 Europe, The Middle East And Africa Cell Counting Market, By Application 6.1 Introduction 6.2 Research 6.3 Diagnostic 6.4 Quality Testing 6.5 Others 9 Geographical Exploration 9.1 Introduction 9.2 Europe 9.2.1 Germany 9.2.2 France 9.2.3 U.K. 9.2.4 Italy 9.2.5 Spain 9.2.6 Rest Of Europe 9.3 Middle East & Africa 10 Competitive Analysis 11 Company Profiles 12 Appendix 12.1 Discussion Blue Print 12.2 Industry Expert Quotes 12.3 Bibliography For more information, please visit https://www.marketresearchfuture.com/reports/europe-cell-counting-market
Song Y.,University of Pittsburgh |
Song Y.,Fudan University |
Bahnson A.,Automated Cell Inc. |
Bahnson A.,Kairos Instruments LLC |
And 9 more authors.
Leukemia | Year: 2010
A deeper understanding of stem cell niche engagement and subsequent behaviors would be enhanced by technologies enabling the tracking of individual stem cells at the clonal level in long-term co-culture (LTC), which mimics the complexity of the bone marrow microenvironment in vivo. Here, we report the application of time-lapse imaging with intermittent fluorescence for tracking well-defined populations of GFP murine hematopoietic stem cells (HSCs) using LTC for 5 weeks. Long-term (LT) and short-term (ST) repopulating HSCs and hematopoietic progenitor cells (HPCs) were compared. The transition from cobblestone areas (CAs) under the stromal cell mantle into dispersed migrating cells on top of the stroma (COS) were directly observed. The ST-HSC and LT-HSC were able to initiate multiple waves of CA formation and COS expansion beyond 2 and 4 weeks, respectively. Retrospective tracking of individual CA forming cell (CAFC) revealed a preference for residing under stroma before the first division and a longer interval before first division for LT-HSC. Inability to maintain quiescence in subsequent divisions was revealed. Our study represents an important starting point from which the LTC system can be augmented to provide a better in vitro model for bone marrow stem cell niches. © 2010 Macmillan Publishers Limited All rights reserved.